Global Biosimilars Market Size, Industry Trends, Share and Forecast 2019-2025Posted by nabeel on January 30th, 2021 The global biosimilars market is estimated to grow at a significant CAGR during the forecast period. The factors that drive the global biosimilars market include the increasing demand for biopharmaceuticals, rising geriatric population, and rapid R&D activities by the players in the field along with technological advancement. Moreover, according to the Pharmaceutical Research and Manufacturers of America (PhRMA) in 2016, the biopharmaceuticals manufacturers located in the US invested billion for R&D activities. Get Free Sample Copy @ https://www.omrglobal.com/request-sample/biosimilars-market
Moreover, the global biosimilars market is also gaining traction owing to the rise in R&D activities that promotes the utilization of alternative medications. With this move, the companies are targeting developing economies that are expected to attract a significant customer base.
R&D by key players to significantly drive the biosimilars market Some of the prominent players operating in the global biosimilars industry include Eli Lilly and Co., Merck & Co. Inc., Mylan NV, Biocon Ltd., Novartis International AG, Allergan Plc., Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals Ltd., and Pfizer Inc., among others. These are the key companies providing various biosimilars in the market. These key manufacturers are adopting various strategies such as new product launches and approvals, merger and acquisition, partnerships and collaborations, and many others in order to thrive in a competitive environment. In November 2018, Sandoz International GmbH, a Novartis company announced the R&D activities for the development of the biosimilar portfolio for unmet access and sustainability needs, and it will not buy US biosimilar rituximab, that will aid the company in enhancing its R&D activities. In September 2019, Sandoz International GmbH, a Novartis company announced that the company has entered into an agreement regarding the proposed natalizumab biosimilar, which is in phase III of the clinical development. Thus, this created more growth opportunities for the company to grow its business. In June 2019, Eli Lily Co. announced the launch of the lower-priced authorized biosimilar version of its diabetes treatment Humalog (insulin lispro) in the US. The launch of new products aids the company to improve its product portfolio. Current Market Trends Covered in the Global Biosimilar Market Report:
Global Biosimilars Market Report- Segmentation By Product
By Applications
Global Biosimilars Market – Segment by Region North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buying From us – 1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation. 4. Our expert research analysts answer all your questions before and after purchasing your report. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/biosimilars-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404 Like it? Share it! More by this author |